Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;150(6):556-561.
doi: 10.1016/j.adaj.2019.01.028.

Oral adverse reactions associated with etoricoxib, a common pain medication

Oral adverse reactions associated with etoricoxib, a common pain medication

Jeremy Edel et al. J Am Dent Assoc. 2019 Jun.

Erratum in

  • Correction.
    [No authors listed] [No authors listed] J Am Dent Assoc. 2019 Sep;150(9):738. doi: 10.1016/j.adaj.2019.07.002. J Am Dent Assoc. 2019. PMID: 31439202 No abstract available.

Abstract

Background and overview: There have been reports of cutaneous adverse reactions to etoricoxib, a frequently used anti-inflammatory and antipain medication. In this report, the authors describe the first series of patients with adverse reactions to etoricoxib restricted to the oral mucosa.

Case description: The series comprised 7 men and 4 women, aged 25 through 81 years, 10 of whom had only oral lesions, 1 with mucocutaneous involvement. Lesions were erosive and aphthouslike or erythema multiformelike. In most of the cases, bilateral involvement of the palate was reported. Lips, tongue, and buccal mucosa were also involved. All lesions resolved after drug discontinuation. In 6 patients, repeated use resulted in recurrence of signs and symptoms similar to the first attack.

Conclusions and practical implications: The dental and medical community should be aware of the oral adverse effects of etoricoxib, recognize them in time, recommend drug-use cessation, and warn patients against repeated use.

Keywords: Etoricoxib; adverse effects; aphthouslike lesions; erosions; erythema multiforme; oral mucosa.

PubMed Disclaimer

Comment in

  • MORE ON ETORICOXIB.
    Marek CL, Hellstein JW. Marek CL, et al. J Am Dent Assoc. 2019 Sep;150(9):735-736. doi: 10.1016/j.adaj.2019.07.015. J Am Dent Assoc. 2019. PMID: 31439199 No abstract available.
  • UNCOMMON ETORICOXIB.
    Wenckus CS. Wenckus CS. J Am Dent Assoc. 2019 Sep;150(9):735. doi: 10.1016/j.adaj.2019.07.014. J Am Dent Assoc. 2019. PMID: 31439200 No abstract available.
  • Editor's response.
    Glick M. Glick M. J Am Dent Assoc. 2019 Sep;150(9):736. doi: 10.1016/j.adaj.2019.07.016. J Am Dent Assoc. 2019. PMID: 31439201 No abstract available.

LinkOut - more resources